How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

16,936 results for

HIV Course

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Sexual and reproductive health and HIV: applying All Our Health

health and HIV. 25 January 2018 Updated the data in the guidance and linked to 'HIV in the UK: 2016 report' instead of '2014 HIV: surveillance, data and management report'. Added a new section about online courses. 4 August 2017 Updated measuring outcomes section to add links to Everyday Interactions measuring impact toolkit and sexual health impact pathway. 1 April 2015 First published. Related content Collection Explore the topic Is this page useful? Thank you for your feedback Help us improve (...) Sexual and reproductive health and HIV: applying All Our Health Sexual and reproductive health and HIV: applying All Our Health - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Sexual and reproductive health

2019 Public Health England

142. Economic evaluations of pre- and post-exposure prophylaxis for HIV

Columbia Centre for Excellence in HIV/AIDS. HIV post-exposure prophylaxis (PEP) guidelines: May 2017. Available from: Accessed November 30, 2018. Kuhar DT, Henderson DK, Struble KA, Heneine W, Thomas V, Cheever LW, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infection Control Hospital Epidemiology. 2013;34(9):875–92. Hankins C, Macklin R, Warren M. Translating PrEP (...) prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Archives of Internal Medicine. 2004;164(1):46–54. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. AIDS. 2004;18(15):2065–73. Herida M, Larsen C, Lot F, Laporte A, Desenclos JC, Hamers FF. Cost-effectiveness of HIV post-exposure prophylaxis in France. AIDS. 2006;20

2019 Ontario HIV Treatment Network

143. Methods to estimate the number of people living with undiagnosed HIV

. Available from: Accessed January 3, 2019. Hughson G. NAM: AIDSMAP. Factsheet: CD4 cell counts. 2017. Available from Accessed December 20, 2018. Hall HI, Song R, Szwarcwald CL, Green T. Brief report: Time from infection with the human immunodeficiency virus to diagnosis, United States. Journal of Acquired Immune Deficiency Syndromes. 2015;69(2):248–51. Song R, Hall HI, Green TA, Szwarcwald CL, Pantazis N. Using CD4 data to estimate HIV incidence, prevalence, and percent of undiagnosed infections (...) (3). Back-calculation was initially used at the beginning of the HIV epidemic; AIDS incidence data was used to “back-calculate” the number of individuals previously infected (16, 17). During this time, effective treatment was not available; the virus took its course, and over time, progressed to AIDS (18). By using the number of reported AIDS cases from each year and the assumed length of time from HIV infection to AIDS (i.e. the incubation period), estimating the number of individuals who

2019 Ontario HIV Treatment Network

144. Public health guidance on HIV, hepatitis B and C testing in the EU/EEA

health guidance on HIV, hepatitis B and C testing in the EU/EEA – An integrated approach 1 Executive summary Reaching and testing those at risk of infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) is still a public health challenge across Europe. One in two people currently living with HIV is diagnosed late in the course of their infection and an even larger proportion of the estimated 9 million Europeans living with chronic hepatitis B or C (...) /EEA European Union/European Economic Area GP General practitioner HA-REACT Joint Action on HIV and Co-Infection Prevention and Harm Reduction HBV Hepatitis B virus HBsAg Hepatitis B surface antigen HCV Hepatitis C virus HIV Human immunodeficiency virus IC Indicator condition IFN Interferon INTEGRATE Joint Action on Integrating Prevention, Testing and Linkage to Care Strategies Across HIV, Viral Hepatitis, TB and STIs in Europe IUSTI International Union Against Sexually Transmitted Infections MSM

2019 European Centre for Disease Prevention and Control - Public Health Guidance

145. Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA

testing Why integrated testing for HIV and viral hepatitis? Why do we need to improve testing for HIV and viral hepatitis? What are the benefits of testing and early diagnosis? One in two people living with HIV are diagnosed late in the course of their infection. A large proportion of the estimated nine million Europeans living with chronic hepatitis B or C are unaware that they are infected. The three viruses have common modes of transmission, and integrated HBV, HCV and HIV testing allows synergies (...) -infection. Integrated testing also reflects existing patterns of service delivery in EU/EEA countries and a growing movement to integrate HIV, HBV and HCV testing, prevention and linkage-to-care efforts. To maximise the benefits of individual treatment for all three infections, it is critical to test and diagnose people as soon as possible in the course of the infection, which is challenging since these infections can typically be asymptomatic for years. The ECDC guidance advocates for the development

2019 European Centre for Disease Prevention and Control - Public Health Guidance

146. Unmet needs of Indigenous peoples living with HIV

Unmet needs of Indigenous peoples living with HIV Unmet needs of Indigenous peoples living with HIV | The Ontario HIV Treatment Network The Ontario HIV Treatment Network Unmet needs of Indigenous peoples living with HIV Unmet needs of Indigenous peoples living with HIV , , , , , , , , , Questions What are the unmet needs of Indigenous peoples living with HIV? What interventions, strategies, and programs have been used to address these needs? Key take-home messages In 2016, First Nations, Métis (...) , and Inuit peoples accounted for 4.9% of the Canadian population but represented 11.3% of all new HIV infections (1). When considering Indigenous health, conventional approaches to HIV and other communicable diseases are insufficient (2). Considerable disconnect exists between the priorities of the HIV care cascade and the experiences of Indigenous peoples living with HIV (3). The lack of coordination between mainstream HIV biomedical approaches and Indigenous worldviews appears to contribute to poor

2019 Ontario HIV Treatment Network

147. The efficacy of post-exposure prophylaxis (PEP) for HIV

and nonoccupational postexposure prophylaxis: Updated version, June 13, 2018. Canadian Medical Association Journal. 2017;189(47):E1448–e58. Kuhar DT, Henderson DK, Struble KA, Heneine W, Thomas V, Cheever LW, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infection Control & Hospital Epidemiology. 2013;34(9):875–92. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R (...) ? What are key factors implicated in the efficacy or inefficacy of PEP? Key take-home messages PEP initiated soon after exposure can reduce the risk of HIV seroconversion after occupational and non-occupational exposures, provided adherence to medications is sufficient (1–4). Evidence suggests that individuals prescribed tenofovir-based two- or three-drug regimens are more likely to complete a course of PEP and have lower discontinuation rates due to adverse events compared to zidovudine-based

2019 Ontario HIV Treatment Network

148. Microbial Translocation and Inflammation Occur in Hyperacute Immunodeficiency Virus Infection and Compromise Host Control of Virus Replication Full Text available with Trip Pro

Microbial Translocation and Inflammation Occur in Hyperacute Immunodeficiency Virus Infection and Compromise Host Control of Virus Replication Within the first three weeks of human immunodeficiency virus (HIV) infection, virus replication peaks in peripheral blood. Despite the critical, causal role of virus replication in determining transmissibility and kinetics of progression to acquired immune deficiency syndrome (AIDS), there is limited understanding of the conditions required to transform (...) abundance of CD4+CCR5+ T cell targets of virus replication, and T cell activation. To test whether increasing gastrointestinal permeability to cause microbial translocation would amplify viremia, we treated two SIV-infected macaque 'elite controllers' with a short-course of dextran sulfate sodium (DSS)-stimulating a transient increase in microbial translocation and a prolonged recrudescent viremia. Altogether, our data implicates translocating microbes as amplifiers of immunodeficiency virus replication

2016 PLoS pathogens

149. 90-90-90 - Charting a steady course to end the paediatric HIV epidemic. Full Text available with Trip Pro

90-90-90 - Charting a steady course to end the paediatric HIV epidemic. The new "90-90-90" UNAIDS agenda proposes that 90% of all people living with HIV will know their HIV status, 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy and 90% of all people receiving antiretroviral therapy will have viral suppression by 2020. By focusing on children, the global community is in the unique position of realizing an end to the paediatric HIV epidemic.Despite (...) treatment to children, adolescents and families. The road to an AIDS-free generation will require bridging the gaps in HIV services and addressing the particular needs of children across the developmental spectrum from infancy through adolescence. To reach the ambitious new targets, innovations and service improvements will need to be rapidly escalated at each step along the prevention-treatment cascade.Charting a successful course to reach the 90-90-90 targets will require sustained political

2015 Journal of the International AIDS Society

150. Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy. Full Text available with Trip Pro

and osteoporosis, which are currently main challenges. It is therefore of major importance to better understand the causes and the phenotypes of immune activation in the course of HIV-1 infection. In this review we will discuss the various causes of immune activation in HIV-1 infected organisms: the presence of the virus together with other microbes, eventually coming from the gut, CD4+ T cell lymphopenia, senescence and dysregulation of the immune system, and/or genetic factors. We will also describe (...) Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy. Systemic immune activation is a striking consequence of HIV-1 infection. Even in virologically suppressed patients, some hyperactivity of the immune system and even of the endothelium and of the coagulation pathway may persist. Apart from immune deficiency, this chronic activation may contribute to various morbidities including atherothrombosis, neurocognitive disorders, liver steatosis

2015 HIV medicine

151. A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses

A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail (...) Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government

2015 Clinical Trials

152. Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France

Hepatitis (Inserm-ANRS): Life-event survey observational survey among migrants in France Additional relevant MeSH terms: Layout table for MeSH terms Hepatitis Hepatitis A HIV Infections Hepatitis, Chronic Hepatitis B Hepatitis B, Chronic Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections Lentivirus Infections Retroviridae Infections Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases (...) Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2015 Clinical Trials

153. TB/HIV co-infections and associated factors among patients on directly observed treatment short course in Northeastern Ethiopia: a 4 years retrospective study Full Text available with Trip Pro

TB/HIV co-infections and associated factors among patients on directly observed treatment short course in Northeastern Ethiopia: a 4 years retrospective study Human immunodeficiency virus (HIV) and tuberculosis (TB) are the leading independent global causes of death among patients with infectious diseases. Additionally, due to the shared immune defense mechanisms, they are the leading cause of co-morbidities globally. However, little information was found regarding the proportion of TB/HIV co (...) -infection in the study area. Thus, this study determined the proportion and associated factors of TB/HIV co-infection.All TB patients treated from January/2011 to December/2014 were included in this study. Data were collected from three health centers namely; Kobo, Robit and Gobiye. Data were entered, cleared, and analyzed using SPSS version 20. Frequency, percentage, median and range were used to present the data. To assess the associated factors, logistic regression was employed.Of the total 990 TB

2015 BMC research notes

154. Post-exposure HIV prophylaxis

who may have been occupationally or sexually exposed to HIV. Once exposed to HIV, there may be a brief period before the infection is established, during which ART may successfully prevent viral replication. Pinto LA, Landay AL, Berzofsky JA, et al. Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIV-contaminated blood. Am J Med. 1997;102:21-24. http://www.ncbi.nlm.nih.gov/pubmed/9845492?tool=bestpractice.com Spira AI, Marx PA, Patterson BK, et (...) al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med. 1996;183:215-225. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192425/ http://www.ncbi.nlm.nih.gov/pubmed/8551225?tool=bestpractice.com PEP should be given as soon as possible following exposure; a 28-day course of treatment is recommended. Fisher M, Briggs E, Cresswell F, et al. UK guideline for the use of post-exposure prophylaxis

2018 BMJ Best Practice

155. Knowledge of HIV and Related Best Practices Among Non-HIV Specific Health Care Providers

, knowledge, and attitudes of human immunodeficien - cy virus screening among adolescents. Journal of Pediatrics 2013;163(6):1711-5. 7. Hughes AK. HIV knowledge and at- titudes among providers in aging: results from a national survey. AIDS Patient Care & STDs 2011;25(9):539-45. 8. Watkins S, Gray J. Human immu- nodeficiency virus/acquired immune deficiency syndrome: a survey of the knowledge, attitudes, and beliefs of Texas registered nurses in the 21st century. Journal for Nurses in Staff Development (...) intervention called SHIP (Sexual Health in Practice) was introduced to improve knowledge and practices among general practitioners (GPs) in relation to sexually transmitted 12. Levison J, Williams LT, Moore A, McFarlane J, Davila JA. Educating health professionals in obstetrics and gynecol- ogy regarding rapid human immunode- ficiency virus (HIV) testing in labor and delivery: A local initiative. Maternal & Child Health Journal 2012;16(9):1748-53. 13. Pillay TD, Mullineux J, Smith CJ, Matthews P

2015 Ontario HIV Treatment Network

156. Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions Full Text available with Trip Pro

Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 (...) March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions

2013 American Heart Association

157. Vaccination of HIV infected children

– 13-valent pneumococcal conjugate vaccine Hib/MenC - Haemophilus influenzae type b and Neisseria meningitidis capsular group C conjugate vaccine MenC - meningococcal capsular group C conjugate vaccine 4CMenB – multicomponent meningococcal capsular group B protein vaccine LAIV – live attenuate influenza vaccine MMR – measles, mumps, rubella vaccine HPV – human papilloma virus vaccine MenACWY – quadrivalent meningococcal capsular groups A, C, W and Y conjugate vaccine Hep A&B – combined hepatitis (...) years old (females & males) Cervical cancer caused by human papillomavirus (HPV) types 16 &18; genital warts caused by types 6 & 11 HPV x 3 doses (0, 1, 6 months) Gardasil Upper arm 14 years old (school year 9) Tetanus, diphtheria and polio Meningococcal groups A, C, W, Y disease Hepatitis A and B dTaP/IPV (check MMR status) MenACWY Hep A and B, booster dose or primary course (if previously unimmunised) Revaxis Nimenrix or Menveo Twinrix or Ambirix Upper arm Upper arm Upper arm Notes: 1. All infants

2018 The Children's HIV Association

158. Canadian HIV Pregnancy Planning Guidelines

Standards Association guidelines for infection control when handling HIV-positive materials and use additional procedures available for the processing of HIV-positive sperm to ensure the preparation of a virus-free sample (III-A). 35. Potentially infectious samples should be processed in a separate laboratory or dedicated area with separate equipment within the main laboratory to reduce the risk of HIV contamination (III-A). 36. Potentially infectious gametes and embryos should be stored (...) Canadian HIV Pregnancy Planning Guidelines No. 354-Canadian HIV Pregnancy Planning Guidelines - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 40, Issue 1, Pages 94–114 No. 354-Canadian HIV Pregnancy Planning Guidelines x Mona Loutfy , MD, MPH (Principal Author) Toronto, ON x V. Logan Kennedy , RN (Principal Author) Toronto, ON x Vanessa Poliquin , MD (Principal Author) Winnipeg, MB x Frederick Dzineku , MD (Principal

2018 Society of Obstetricians and Gynaecologists of Canada

159. HIV

contact us via jon.brassey@tripdatabase.com Top results for hiv 1. HIV infection and AIDS HIV infection and AIDS - NICE CKS Clinical Knowledge Summaries Share HIV infection and AIDS - Summary The Human Immunodeficiency Virus ( HIV ) is a retrovirus that preferentially infects and destroys cells of the immune system, in particular the CD4 cells (a class of T lymphocyte, also known as T helper cells). There are 2 main types of HIV : HIV -1 (the predominant type in the UK) is highly virulent and is found (...) Management in Australia has developed specific clinical guidance on the topic of when to start antiretroviral therapy in people with HIV . Key considerations concerning the issue 2011 9. Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection ( HIV /TBL) Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection ( HIV /TBL) - Full Text View - ClinicalTrials.gov A service of the U.S. National Institutes

2018 Trip Latest and Greatest

160. Bictegravir / emtricitabine / tenofovir alafenamide / fumarate (Biktarvy) - HIV Infections

substance: Bictegravir / Emtricitabine / Tenofovir Alafenamide International Non-proprietary Name/Common Name: Bictegravir / Emtricitabine / Tenofovir Alafenamide Pharmaco-therapeutic group (ATC Code): Direct acting antivirals, antivirals for treatment of HIV infections, combinations (J05AR) Therapeutic indication(s): Biktarvy is indicated for the treatment of adults infected with human immunodeficiency virus 1 (HIV 1) without present or past evidence of viral resistance to the integrase inhibitor class (...) Practice GEN elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (coformulated; Genvoya®) GI gastrointestinal GLSM geometric least-squares mean GS-9883 bictegravir HBeAb hepatitis B e antibody HBeAg hepatitis B e antigen HBsAb hepatitis B surface antibody HBsAg hepatitis B surface antigen HBV hepatitis B virus HCV hepatitis C virus HDPE High Density Polyethylene HIV human immunodeficiency virus HIV-1 human immunodeficiency virus type 1 HLA human leukocyte antigen HPLC High performance liquid

2018 European Medicines Agency - EPARs

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>